Cuur Diagnostics

Skin and Wound Panel

SKIN & WOUND PANEL

CUUR DiagnosticsTM is dedicated to maintaining the largest data set of infectious disease targets available in the world.

Acute and chronic wounds have become a significant healthcare problem in the US and as well as globally. Rapid and comprehensive identification of pathogens is critical to mitigate the risk of an acute infection becoming chronic, especially where patients with venous ulcers, diabetic ulcers or pressure ulcers who frequently suffer from prolonged failure to heal and may progress to the need for amputation. Correctly identifying the cause of a chronic wound as well as the local and systemic factors that may be contributing to poor wound healing is critical to successful wound treatment.

CUUR Diagnostics provides the most comprehensive examination of the bacterial and fungal organisms available on the market empowering providers in wound diagnostics, limb preservation, avoidance of adverse events and prevention of unnecessary antibiotic prescribing.

Helix DNA
TARGETS

Gram Negative Bacteria 
BacteriaKlebsiella pneumoniae
BacteriaKlebsiella oxytoca
BacteriaEscherichia coli
BacteriaEnterobacter aerogenes
BacteriaAcinetobacter baumannii
BacteriaPseudomonas aeruginosa
BacteriaProteus mirabilis
BacteriaBartonella henselae
BacteriaStenotrophomonas maltophilia
BacteriaBacteroides fragilis

Gram Positive Bacteria 
BacteriaStaphylococcus aureus
BacteriaStreptococcus agalactiae
BacteriaStreptococcus pyogenes
BacteriaStaphylococcus epidermidis
BacteriaEnterococcus faecalis
BacteriaStreptococcus dysgalactiae
BacteriaCorynebacterium riegelii
BacteriaFinegoldia magna (Peptostreptococcus magnus)
BacteriaClostridium perfringens
BacteriaPeptostreptococcus anaerobius
BacteriaPropionibacterium acnes

Fungal 
FungalStaphylococcus aureus
FungalStreptococcus agalactiae
FungalStreptococcus pyogenes

AbR 
AbRESBL, blaOXA
AbRMethicillin, mecA
AbRESBL, blaKPC
AbRVancomycin, vanA
AbRVancomycin, vanB
AbRAminoglycoside, aac(6’)-lb-cr
AbRMacrolide, ermB
AbRAmpicillin, ampC
AbRTetracycline, tetS
AbRQuinolone, qnrA
AbRQuinolone, qnrS
AbRCarbapenem Resistance, oxa-48

Infectious Disease Care

D I A G N O S T I C S

STATISTICALLY SPEAKING
  • In the US, 8.2 million patients receiving Medicare benefits suffer from chronic wounds
  • Medicare spends over $32 billion annually on wound treatment.